Health Care [ 4/12 ] | Biotechnology [ 13/75 ]
NASDAQ | Common Stock
Recursion Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States and the United Kingdom.
The company develops REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-617, which is in Phase 1/2 clinical trial to treat advanced solid tumors; REC-1245, which is in Phase 1/2 clinical trial to treat biomarker-enriched solid tumors and lymphoma; REC-3565 that is in Phase 1/2 for the treatment of relapsed or refractory B-cell malignancies; and REC-4539, a reversible, CNS penetrant, orally bioavailable, and potential best-in-class inhibitor of LSD1 for the treatment of solid tumors and hematology oncology.
Its preclinical stage product includes REC-7735 for the treatment of HR+ breast cancer; and REC-102 for the treatment of hypophosphatasia.
The company has collaboration and agreement with Roche & Genentech; Sanofi; Bayer AG; Tempus; and Takeda Pharmaceutical Company Limited.
Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Feb 25, 26 | -0.21 Increased by +60.38% | -0.30 Increased by +30.00% |
| Nov 5, 25 | -0.36 Decreased by -5.88% | -0.37 Increased by +2.70% |
| Aug 5, 25 | -0.41 Decreased by -2.50% | -0.35 Decreased by -17.14% |
| May 7, 25 | -0.50 Decreased by -28.21% | -0.52 Increased by +3.10% |
| Feb 25, 25 | -0.53 Decreased by -26.19% | -0.42 Decreased by -27.16% |
| Nov 6, 24 | -0.34 Increased by +20.93% | -0.35 Increased by +2.86% |
| Aug 8, 24 | -0.40 Decreased by -5.26% | -0.40 |
| May 9, 24 | -0.39 Decreased by -14.71% | -0.42 Increased by +7.14% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 25 | 35.54 M Increased by +687.81% | -108.12 M Increased by +39.56% | Decreased by -304.25% Increased by +92.33% |
| Sep 30, 25 | 5.17 M Decreased by -80.16% | -162.25 M Decreased by -69.59% | Decreased by -3.14 K% Decreased by -754.72% |
| Jun 30, 25 | 19.10 M Increased by +32.62% | -171.90 M Decreased by -76.23% | Decreased by -899.84% Decreased by -32.88% |
| Mar 31, 25 | 14.74 M Increased by +9.30% | -202.49 M Decreased by -121.60% | Decreased by -1.37 K% Decreased by -102.76% |
| Dec 31, 24 | 4.51 M Decreased by -57.54% | -178.91 M Decreased by -92.38% | Decreased by -3.97 K% Decreased by -353.08% |
| Sep 30, 24 | 26.08 M Increased by +158.19% | -95.67 M Decreased by -2.86% | Decreased by -366.82% Increased by +60.16% |
| Jun 30, 24 | 14.40 M Increased by +30.76% | -97.54 M Decreased by -27.13% | Decreased by -677.17% Increased by +2.77% |
| Mar 31, 24 | 13.49 M Increased by +11.18% | -91.37 M Decreased by -39.87% | Decreased by -677.29% Decreased by -25.80% |